Importantly, while before Orkambi® treatment the CF patient-derived MNCs expressed only a barely detectable immature band B of F508del-CFTR, after 6 and 12 months of treatment, there was an increase in the expression also of the mature band C of F508del CFTR protein (Figure 3B). The gene discussed is CFTR; the disease is cystic fibrosis.